Synonyms: Compound A [WO2022237720] | JNJ-75276617 | JNJ75276617
Compound class:
Synthetic organic
Comment: The structure for bleximenib was obtained from proposed INN list 129 (August 2023). This maps to a PubChem CID that describes it as a menin-mixed-lineage leukemia 1 (menin-MLL) inhibitor. The compound is claimed in patent WO2022237720A1 (Janssen, Johnson & Johnson), for potential to treat hematological malignancies (in combination with a BCL-2 inhibitor) [1]. This class of agents disrupts the interaction between MLL oncoproteins (re-arranged MLL fusion proteins that are found in aggressive human acute leukemias) and the tumour suppressor protein menin (MEN1, O00255). Menin is an essential oncogenic co-factor for the leukemogenicity of MLL fusion proteins. The INN was subsequently mapped to the company code JNJ-75276617 [2].
|
|
Bioactivity Comments |
Inhibits menin interaction with the MLL menin binding motif 1 (MBM1) peptide in an HTRF assay with IC50 of 0.09 nM |